Status:
UNKNOWN
Ropivacaine Use in Femoral Nerve Block; What is the Minimal Effective Analgesic Concentration (MEAC 90)
Lead Sponsor:
Healthpoint Hospital
Conditions:
Postoperative Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The aim of this study is to determine the minimal effective ropivacaine concentration required to provide adequate analgesic femoral nerve block in 90% of patients (MEAC90)
Detailed Description
* Before induction of GA, all patients will receive sciatic, obturator, lateral femoral cutaneous and femoral nerve blocks. * The femoral nerve block will be performed using 15ml of ropivacaine which ...
Eligibility Criteria
Inclusion
- Patients, who are scheduled for knee ligament reconstruction
Exclusion
- \<18 y,
- ASA physical class greater \>III
- BMI \>40 has any contraindication for medications or techniques used in the study
Key Trial Info
Start Date :
May 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2021
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT04834440
Start Date
May 1 2021
End Date
September 30 2021
Last Update
April 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Healthpoint Hospital
Abu Dhabi, United Arab Emirates, 112308